← Evidence map

ArticleFrontiers in immunology2026

Enzyme replacement therapy (ERT) combined with transient low-dose methotrexate (TLD-MTX) results in age- and disease-dependent immune profile changes in Infantile- vs. late-onset Pompe disease patients.

Parisa Amirifar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Enzyme replacement therapy (ERT) combined with transient low-dose methotrexate (TLD-MTX) results in age- and disease-dependent immune profile changes in Infantile- vs. late-onset Pompe disease patients. | OpenQuestion